Astana Biomed Group, an authorized Abcam distributor in Central Asia

Human MKNK1 (MNK1) knockout HeLa cell lysate (ab258516)

Overview

  • Product name

    Human MKNK1 (MNK1) knockout HeLa cell lysate

  • Product overview


    Knockout cell lysate achieved by CRISPR/Cas9.

  • Parental Cell Line

    HeLa

  • Organism

    Human

  • Mutation description

    Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and Insertion of the selection cassette in exon2.

  • Passage number

  • Knockout validation

    Sanger Sequencing

  • Reconstitution notes

    To use as WB control, resuspend the lyophilizate in 50 µL of LDS* Sample Buffer to have a final concentration of 2 mg/ml. For reducing conditions, we recommend a final concentration of 0.1 M DTT.

    *Usage of SDS sample buffer is not recommended with these lyophilized lysates.

  • Notes

    Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version - found here. Please refer to our lysis protocol for further details on how our lysates are prepared.

    User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

    Access thousands of knockout cell lysates, generated from commonly used cancer cell lines.
    See here for more information on knockout cell lysates.

    Abcam has not and does not intend to apply for the REACH Authorisation of customers’ uses of products that contain European Authorisation list (Annex XIV) substances.
    It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

    This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Properties

Target

  • Function

    May play a role in the response to environmental stress and cytokines. Appears to regulate transcription by phosphorylating EIF4E, thus increasing the affinity of this protein for the 7-methylguanosine-containing mRNA cap.

  • Tissue specificity

    Ubiquitous.

  • Sequence similarities

    Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family.
    Contains 1 protein kinase domain.

  • Post-translational
    modifications

    Dual phosphorylation of Thr-250 and Thr-255 activates the kinase. Phosphorylation of Thr-385 activates the kinase.

  • Cellular localization

    Cytoplasm and Cytoplasm. Nucleus.
  • Information by UniProt

  • Alternative names

    • MAP kinase interacting kinase 1
    • MAP kinase interacting serine/threonine kinase 1
    • MAP kinase signal integrating kinase 1
    • MAP kinase signal-integrating kinase 1
    • MAP kinase-interacting serine/threonine-protein kinase 1
    • MAPK signal integrating kinase 1
    • MITOGEN-ACTIVATED PROTEIN KINASE-INTERACTING SERINE/THREONINE KINASE 1
    • mknk1
    • MKNK1_HUMAN
    • MNK 1
    • Mnk1
    see all

Properties

Images

  • Sanger Sequencing - Human MKNK1 knockout HeLa cell lysate (ab258516)
    Sanger Sequencing - Human MKNK1 knockout HeLa cell lysate (ab258516)

    Allele-1: 1 bp deletion in exon2

     

  • Sanger Sequencing - Human MKNK1 knockout HeLa cell lysate (ab258516)
    Sanger Sequencing - Human MKNK1 knockout HeLa cell lysate (ab258516)

    Allele-2: Insertion of the selection cassette in exon2

     

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Clear all

Recently viewed products

Sign up